Drug Profile
Idronoxil - Kazia Therapeutics/Noxopharm
Alternative Names: NOX-66; VeyondaLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Noxopharm
- Developer Children Cancer Institute; Kazia Therapeutics; Noxopharm
- Class Anti-infectives; Anti-inflammatories; Antineoplastics; Antivirals; Hormones; Isoflavones; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Cyclin-dependent kinase inhibitors; MPYS protein inhibitors; Sphingosine kinase inhibitors; Src-Family kinase modulators; TBK1 protein inhibitors; Tumour-associated NADH oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- Phase I/II Prostate cancer
- Phase I Soft tissue sarcoma
- Preclinical Nasopharyngeal cancer; SARS-CoV-2 sepsis
- Research Influenza virus infections
- No development reported COVID 2019 infections; Diffuse intrinsic pontine glioma
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in Moldova (Rectal, Suppository)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in Georgia (Rectal, Suppository)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in New Zealand (Rectal, Suppository)